Sofosbuvir: Difference between revisions

In February 2015, it was reported<ref>{{cite web|title=Doctors of the World—Médecins Du Monde opposes sofosbuvir patent in Europe|url=http://www.medecinsdumonde.org/gb/Doctors-of-the-World-Medecins-du-Monde-is-filing-a-patent-challenge-to-Gilead-s-patent-on-sofosbuvir-at-the-European-Patent-Office|publisher=Médecins du Monde|access-date=12 February 2015|url-status=live|archive-url=https://web.archive.org/web/20150212143338/http://www.medecinsdumonde.org/gb/Doctors-of-the-World-Medecins-du-Monde-is-filing-a-patent-challenge-to-Gilead-s-patent-on-sofosbuvir-at-the-European-Patent-Office|archive-date=12 February 2015 }}</ref> that [[Doctors of the World]] had submitted an objection to Gilead's patent<ref>{{cite web|title=European Patent EP2203462, granted 21 May 2014|url=https://register.epo.org/espacenet/regviewer?AP=08732818&CY=EP&LG=en&DB=REG|website=European Patent Register|publisher=European Patent Office|access-date=12 February 2015}}</ref> at the [[European Patent Office]], claiming that the structure of sofosbuvir is based on already known molecules.<ref name=spiegel2015>{{cite magazine |url=http://www.spiegel.de/wissenschaft/medizin/sovaldi-aerzte-der-welt-erhebt-einspruch-gegen-patent-a-1017728.html | vauthors = Kuhrt N |title=Hepatitis-Pille Sovaldi: "Ärzte der Welt" geht gegen Patent vor | trans-title = Hepatitis pill Sovaldi: "Doctors of the World" takes action against the patent |magazine=[[Der Spiegel]] |language=de |date=February 10, 2015 |access-date=February 10, 2015 |url-status=live |archive-url=https://web.archive.org/web/20150210201434/http://www.spiegel.de/wissenschaft/medizin/sovaldi-aerzte-der-welt-erhebt-einspruch-gegen-patent-a-1017728.html |archive-date=February 10, 2015 }}</ref> In particular, Doctors of the World argued that the [[Protide]] technology powering sofosbuvir was previously invented by the [[Chris McGuigan]] team at [[Cardiff University]] in the UK, and that the Gilead drug is not therefore inventive.<ref>{{cite news|title=Conflit autour d'un traitement contre l'hépatite C| newspaper=Le Monde.fr | url=http://www.lemonde.fr/planete/article/2015/02/10/conflit-autour-d-un-traitement-contre-l-hepatite-c_4573300_3244.html |language=fr |date=February 10, 2015 |access-date=March 4, 2015}}</ref><ref>{{cite web|title=Charity challenges Gilead's European patent on hepatitis C therapy Sovaldi|url=http://www.firstwordpharma.com/node/1263122#axzz3RPviNrRF|date=February 10, 2015|access-date=March 4, 2015|url-status=live|archive-url=https://web.archive.org/web/20150402095143/http://www.firstwordpharma.com/node/1263122 |archive-date=April 2, 2015 }}</ref> The group filed challenges in other developing countries as well.<ref>{{cite news|url=https://www.nytimes.com/2015/05/20/business/high-cost-of-hepatitis-c-drug-prompts-a-call-to-void-its-patents.html|title=High Cost of Sovaldi Hepatitis C Drug Prompts a Call to Void Its Patents | work = The New York Times |date=20 May 2015 |url-status=live|archive-url=https://web.archive.org/web/20150523082146/http://www.nytimes.com/2015/05/20/business/high-cost-of-hepatitis-c-drug-prompts-a-call-to-void-its-patents.html?_r=0|archive-date=2015-05-23 | vauthors = Pollack A }}</ref> These challenges were unsuccessful.<ref>{{cite web |website=https://www.doctorsoftheworld.org.uk/news/european-patent-office-maintain-patent-on-hepatitis-c-drug-sofosbuvir |access-date=30 November 2024}}</ref>